The Innovative Cancer Vaccine and Immunotherapy Research Center of Minkai Biomedical has been officially inaugurated in Lisbon, accelerating China–Europe collaboration and strengthening leadership in the cancer peptide vaccine field
On October 18th, the core team of Minkai Biomedical visited the Champalimaud Foundation in Lisbon, Portugal, which marked the full launch of the strategic collaboration between the two
parties. During the exchange, both sides clarified specific details such as clinical trial indications and R&D pipelines, signifying Minkai Biomedical's deep involvement in the research, development, and clinical advancement of cancer vaccines. Simultaneously, the "Innovative Cancer Vaccine and Immunotherapy Research Center" was officially inaugurated at the Champalimaud Foundation, providing tangible support for in-person collaboration and the implementation of clinical studies. The core research and clinical teams from both sides have been fully established and are now fully engaged, initiating a new chapter of practical cooperation in China-Europe cancer immunotherapy.
